EUVIMEDEUVIMED entdecken
Crossref

Efficacy and safety of anti‐interleukin‐1 in children with colchicine‐resistant familial Mediterranean fever

Hatice Kubra Erkilet iD, Deniz Gezgin Yildirim iD, Pelin Esmeray iD, Oğuz Söylemezoğlu iD

Pediatrics International · 2023

DOI: 10.1111/ped.15588 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatrics International, 2023. Verfasst von Hatice Kubra Erkilet und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Faculty of Medicine, Gazi University, Ankara, Turkey. Hauptthemen laut MEDLINE: Familial Mediterranean Fever, Amyloidosis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The aim of this study was to evaluate the efficacy and safety of anti‐interleukin‐1 (IL‐1) therapies in colchicine‐resistant pediatric patients with familial Mediterranean fever (FMF).

Methods

In this study, we retrospectively evaluated 656 children with FMF and 27 patients who had been treated with anti‐IL‐1 therapies (anakinra/canakinumab) . Clinical and laboratory features, MEFV gene mutations, treatment responses were investigated.

Results

Twenty of the patients were treated with anakinra (the treatment of 6 patients who initially used anakinra was switched to canakinumab in the follow‐up period), and 13 patients were treated with canakinumab. Clinical symptom and severity scores decreased in all patients A decrease in acute phase reactants was also observed in patients. A total of 18 (66%) patients had a M694V homozygous mutation, while 24 (89%) patients had a M694V mutation, at least in one allele.

Conclusions

FMF patients with colchicine resistance may progress to amyloidosis. IL‐1 antagonist treatment could be used safely with a favorable outcome in pediatric patients with FMF resistance to colchicine therapy and/or who have renal amyloidosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Familial Mediterranean FeverAmyloidosisHumansChildColchicineInterleukin 1 Receptor Antagonist ProteinInterleukin-1Retrospective StudiesPyrin

Stichwörter der Autor:innen

amyloidosisanakinracanakinumabchildrenfamilial Mediterranean fever

Substanzen

ColchicineInterleukin 1 Receptor Antagonist ProteinInterleukin-1MEFV protein, humanPyrin

Autor:innen und Institutionen

  • Department of Pediatrics, Faculty of Medicine, Gazi University, Ankara, Turkey.
  • Department of Pediatric Rheumatology, Faculty of Medicine, Gazi University, Ankara, Turkey.

ORCID-Profile: Hatice Kubra Erkilet, Deniz Gezgin Yildirim, Pelin Esmeray, Oğuz Söylemezoğlu

Zitieren

APA

Erkilet, H. K., Gezgin Yildirim, D., Esmeray, P., & Söylemezoğlu, O. (2023). Efficacy and safety of anti‐interleukin‐1 in children with colchicine‐resistant familial Mediterranean fever. Pediatrics International. https://doi.org/10.1111/ped.15588

Vancouver

Erkilet HK, Gezgin Yildirim D, Esmeray P, Söylemezoğlu O. Efficacy and safety of anti‐interleukin‐1 in children with colchicine‐resistant familial Mediterranean fever. Pediatrics International. 2023. doi:10.1111/ped.15588

BibTeX
@article{Erkilet2023,
  author = {Erkilet, Hatice Kubra and Gezgin Yildirim, Deniz and Esmeray, Pelin and Söylemezoğlu, Oğuz},
  title = {Efficacy and safety of anti‐interleukin‐1 in children with colchicine‐resistant familial Mediterranean fever},
  journal = {Pediatrics International},
  year = {2023},
  doi = {10.1111/ped.15588}
}
Kostenlos starten →